News | October 1, 2018

Kit Check Closes the Diversion Gap with Launch of Bluesight IRIS and Reveals Which Hospital Employees Exhibit Behaviors Consistent with Controlled Substance Theft Ava Mutchler Leading Automated Medication Solutions Provider for Hospital Pharmacies Leverages Machine...

News | November 26, 2018

Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company -Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer-...

News | November 29, 2018

PRINCIPIA BIOPHARMA REPORTS POSITIVE PRN1008 PHASE 2 TOP-LINE RESULTS AND INITIATES PHASE 3 PEMPHIGUS PROGRAM November 29, 2018 at 4:01 PM EST – Achieved Phase 2 primary endpoint – over 50% of patients attained Control of Disease Activity within four weeks of...

News | November 9, 2018

HARPOON THERAPEUTICS UNVEILS PROTRITAC PLATFORM: A NOVEL, PROTEASE-ACTIVATED T CELL ENGAGER PLATFORM DESIGNED TO ACCESS A BROAD LANDSCAPE OF SOLID TUMOR TARGETS Preclinical Proof-of-Concept Data Presented at the 2018 Society for Immunotherapy of Cancer (SITC) Annual...

News | November 11, 2018

HARPOON THERAPEUTICS ANNOUNCES CLOSING OF $70M SERIES C FINANCING Proceeds to Advance Pipeline of Cancer Immunotherapies South San Francisco, CA – November 11, 2018 – Harpoon Therapeutics, Inc. (“Harpoon”), a clinical-stage immunotherapy company developing a novel...

News | November 12, 2018

Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans Studies in Healthy Human Volunteers Reinforce Mechanism of Action Observed in Preclinical Studies EVANSTON, Ill.,...
sem, commodo ultricies ut Nullam suscipit sit